Portfolio company
Droia
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This venture capital firm develops therapeutics for oncology and genetic diseases for patients with unmet medical needs.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Dania Therapeutics
The company develops small-molecule therapies targeting cancer metabolism to treat acute myeloid leukaemia and other life-threatening cancers for medical patients.
ProteoValent Therapeutics
This company develops targeted protein degrader therapies for cancer and haematology patients.
Forma
This company develops small molecule therapies for patients with sickle cell disease and cancer.
Borea Therapeutics
The company develops bio-conjugated viral vectors for gene therapy to treat patients with genetic or chronic diseases.
Enodia
This company develops small-molecule therapies that degrade disease-causing proteins at the point of synthesis for patients with cancer and inflammatory diseases.
Rocket Pharma
This company develops gene therapies for patients with rare and devastating genetic cardiovascular and haematological diseases.
UPPTHERA
The company develops targeted protein degradation therapies for patients with cancer and rare diseases and provides platform technologies to pharmaceutical and biotechnology companies.
1200 Pharma
This biotechnology firm develops small molecule therapies and drug intellectual property for the treatment of cancer patients.